Blog
RSS FeedPosted by Michael Wonder on 17 May 2016
Brivaracetam in epilepsy: additional benefits not seen by IQWiG
17 May 2016 - No directly comparative study; the indirect comparisons are unusable. ...
Posted by Michael Wonder on 17 May 2016
Vismodegib for basal cell carcinoma: additional benefits still not seen says Germany's IQWiG
17 May 2016 - Submitted data deemed to be unsuitable. ...
Posted by Michael Wonder on 02 May 2016
Ibrutinib: indication of an additional clinical benefit in one of three therapeutic indications
2 May 2016 - The IQWIG in Germany has found ibrutinib has an additional clinical benefit for certain patients with ...
Posted by Michael Wonder on 02 May 2016
Umeclidinium for symptom relief in COPD: additional benefit is not proven
2 May 2016 - No sighificant differences for moderate disease and no data for severe disease. ...
Posted by Michael Wonder on 02 May 2016
Mepolizumab in severe asthma: additional benefit is not proven
2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...
Posted by Michael Wonder on 08 Apr 2016
Additional benefit of crizotinib for the first-line treatment of bronchial carcinoma is not proven
1 April 2016 - Crizotinib (Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) ...
Posted by Michael Wonder on 06 Apr 2016
Genvoya in HIV: positive effects predominate in some adults, negative effects in others says Germany's IQWiG
1 April 2016 - The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the ...
Posted by Michael Wonder on 04 Apr 2016
Efmoroctocog alfa for haemophilia A: IQWIG says an additional benefit is not proven
1 April 2016 - Efmoroctocog alfa (trade name: Elocta) has been approved since November 2015 for people with type A haemophilia. ...
Posted by Michael Wonder on 02 Apr 2016
HIV-positive children and adolescents: additional benefit of rilpivirine not proven
1 April 2016 - Under the trade name Edurant, rilpivirine hydrochloride as single agent has been approved already since 2011 for ...
Posted by Michael Wonder on 19 Mar 2016
Addendum on regorafenib in metastatic colorectal cancer: added benefit no longer proven
17 March 2016 - The drug manufacturer presented further analyses; the additional disadvantages outweigh the survival advantage. ...
Posted by Michael Wonder on 19 Mar 2016
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
17 March 2016 - Study data subsequently submitted allow quantification / still major added benefit for women. ...
Posted by Michael Wonder on 16 Mar 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: little additional value says Germany's IQWiG
15 March 2016 - TheIQWiG found more positive and negative patient-relevant outcomes, which tend to cancel each other. There ...
Posted by Michael Wonder on 15 Mar 2016
Secukinumab for active ankylosing spondylitis or psoriatic arthritis; no additional clinical benefit says Germany's IQWiG
15 March 2016 - Since Novartis cited no adequate studies, an additional benefit of secukinumab versus the appropriate comparator therapies has ...
Posted by Michael Wonder on 01 Mar 2016
Fingolimod in multiple sclerosis: no evidence of additional benefits in the new application
1 March 2016 - This assessement was about patients with highly active relapsing-remitting multiple sclerosis, on a full and adequate course ...
Posted by Michael Wonder on 01 Mar 2016
Aflibercept in myopic choroidal neovascularisation: additional benefits not covered
1 March 2016 - Since the manufacturer provides no adequate studies, an additional benefit of aflibercept versus the appropriate comparator therapy ...